Efforts at Rubella Elimination in the United States: The Impact of Hemispheric Rubella Control
|
|
- Oswin Hunter
- 5 years ago
- Views:
Transcription
1 SUPPLEMENT ARTICLE Efforts at Rubella Elimination in the United States: The Impact of Hemispheric Rubella Control Gustavo H. Dayan, 1 Carlos Castillo-Solórzano, 2 Margarita Nava, 3 Bradley S. Hersh, 4 Jon Andrus, 2 Romeo Rodríguez, 3 and Susan E. Reef 1 1 National Center for Immunization and Respiratory Diseases (proposed), Centers for Disease Control and Prevention, Atlanta, Georgia; 2 Pan American Health Organization, Washington, DC; 3 National Center for the Health of Infants and Adolescents, Secretary of Health, Mexico DF, Mexico; and 4 World Health Organization, Geneva, Switzerland We examined rubella vaccination trends, rubella surveillance, and disease patterns for the Americas, Mexico, and the United States, to evaluate the impact of hemispheric rubella control on rubella elimination in the United States during In 1997, 130,375 rubella cases were reported in the Americas, with 38,042 reported in Mexico. Over the next 7 years, a rubella control initiative resulted in the administration of 110 million rubella-containing vaccine doses in Latin America, with 77.7 million doses administered within Mexico. By 2004, the number of reported rubella cases had declined to 3103 in the Americas and 698 in Mexico. Concurrently, the number of rubella cases in the United States fell from 817 during to!25 cases/ year from 2001 onward, with loss of seasonality and geographic clustering, despite no change in vaccination rates. Implementation of rubella control strategies in the Americas, particularly in Mexico, appears to have facilitated rubella elimination in the United States. Rubella vaccine was licensed in the United States in 1969, and the ensuing 2 decades saw a dramatic decline in disease rates [1], although viral transmission continued. In 1989, a goal to eliminate indigenous rubella transmission and congenital rubella syndrome (CRS) was established for the year In pursuit of the elimination goal, childhood rubella vaccination coverage was increased to 190% [2] during the 1990s, and, by the end of the decade, overall population immunity levels surpassed the threshold thought to ensure interruption of viral transmission [3]. Nevertheless, hundreds of cases of rubella continued to be reported every year in the United States. The demographics of rubella disease in the 1990s revealed a problem difficult to solve solely within the United States. For instance, in 1999, 65% of cases with known country of origin were among persons born outside the United Reprints or correspondence: Dr. Gustavo H. Dayan or Dr. Susan E. Reef, National Center for Immunization and Respiratory Diseases (proposed), Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, MS A-47, Atlanta, GA or sreef@cdc.gov). Clinical Infectious Diseases 2006; 43:S by the Infectious Diseases Society of America. All rights reserved /2006/4309S3-0007$15.00 States and, of these, 98% were from the Western Hemisphere, with 81% from Mexico [1]. The year 2000 saw 176 confirmed cases of rubella and 9 cases of CRS, and the goal of rubella elimination was deferred to The World Health Organization (WHO) had not included rubella vaccine in the Expanded Program on Immunization (EPI) in 1974 [4], and, until the late 1990s, no formal rubella vaccination program existed within the region of the Americas. However, in 1997, a regionwide control initiative was adopted for the Americas, and in 2000 the WHO recommended use of rubella vaccine in all countries with well-functioning childhood immunization programs where prevention of CRS or elimination of rubella was considered to be a public health priority and where resources could be mobilized to ensure implementation of an appropriate strategy [5]. Beginning in 2001, the epidemiological profile of rubella in the United States appeared to change: the number of cases markedly diminished, the seasonal peak was lost, and individual cases were isolated temporally and geographically [6]. This occurred in the absence of any marked alteration in vaccination coverage within the United States [2] but in a context of an increasingly vigorous rubella control program in the Americas. This S158 CID 2006:43 (Suppl 3) Dayan et al.
2 suggested that hemispheric rubella vaccination control may have played an important role in helping to reduce rubella disease to elimination levels within the United States. To address this question, we comparatively examined the history of rubella vaccination programs, vaccination trends, rubella surveillance, and rubella disease patterns for the WHO Region of the Americas, Mexico, and the United States. METHODS We compared the rubella vaccination programs and temporal patterns of disease in the United States with those in the Western Hemisphere and Mexico, focusing on , the period during which the epidemiological profile of rubella disease in the United States changed to an elimination pattern. Region of the Americas. We obtained information from the records of the Pan American Health Organization (PAHO), the regional body of the WHO responsible for health issues of the 35 nations and 9 territories in the Western Hemisphere. To examine the history of vaccination policies and programs, we reviewed minutes of conferences dealing with rubella issues, recommendations of technical advisory bodies, reports published in PAHO bulletins, and guidelines developed by working groups. To examine vaccination trends, we reviewed rubella vaccine doses administered as reported by Latin American countries (i.e., all countries in the Region of the Americas, excluding Canada, the United States, and the English-speaking Caribbean) to the Immunization Unit of the PAHO. These reports were divided into first doses administered as part of routine vaccination programs and doses administered as part of national campaigns, which may target both adults and children without regard to previous vaccination status. To examine rubella surveillance and disease trends, we reviewed the reports of rubella disease and CRS by participating nations to the PAHO. Mexico. For the history of vaccination policies and programs and for patterns of rubella disease and congenital rubella syndrome, we obtained information from the National Center for the Health of Infants and Adolescents, Secretary of Health, Mexico, where we also obtained data concerning doses of rubella vaccine administered. United States. By methods described in detail elsewhere, we examined reports of rubella disease [6] and rubella vaccine doses administered and childhood coverage [2]. We also examined patterns of rubella disease imported into the United States from Mexico and other nations in the Americas. RESULTS Region of the Americas Rubella vaccination programs. Before 1990, only 6 of the 44 nations/territories in the region included rubella vaccine in their routine childhood vaccination programs. In 1997, the PAHO Technical Advisory Group on Vaccine Preventable Diseases recommended the implementation of a regional initiative to enhance prevention of rubella and CRS. A strategy for accelerated rubella control and CRS prevention was developed [7]. This strategy included the introduction of rubella-containing vaccines into the routine childhood immunization programs administered at 12 months of age and a 1-time measles-rubella (MR) vaccination campaign for adults to interrupt rubella virus circulation among men and women of childbearing age. Additional vaccination strategies initially used to achieve measles elimination included achievement and maintenance of high routine vaccination coverage ( 95%) with measles-mumpsrubella (MMR) vaccine (i.e., keep up vaccination) and follow-up campaigns with MR vaccine. By 2004, all but 1 nation (Haiti) in the region had incorporated rubella-containing vaccine into their national vaccination program [8]. Of the 44 nations/territories, 24 had also conducted rubella vaccination campaigns for adults [8], with varying target groups based on patterns of susceptibility and fertility. Most of the countries in the English-speaking Caribbean targeted both men and women years of age [9] in vaccination campaigns conducted during Chile organized a vaccination campaign targeting only females years of age in 1999 [10]. Costa Rica targeted individuals of both sexes years of age in 2001 [11]. Brazil conducted a vaccination campaign in , targeting women years of age; however, some states adjusted the target age group [12]. Vaccination campaigns targeting both men and women were conducted in Honduras in 2002, in El Salvador in 2004, and in Ecuador in 2004 [8]. In September 2003, a goal of hemispheric rubella eradication was established for 2010 [13, 14]. Indicators of rubella vaccination. The birth cohort for Latin America is estimated to be million, and the total population is estimated to be 543 million [15]. The annual number of first doses administered routinely to children increased from 5.4 million in 1997 to 9.6 million in 2004 (figure 1A). These data do not include doses delivered during the same period as part of mass campaigns, which are estimated at a total of million. Therefore, 110 million doses of rubellacontaining vaccine were administered in Latin America during the period Rubella/CRS surveillance. Before 1992, only 4 nations/territories reported rubella cases to PAHO. In 1994, a measles surveillance system was implemented [16] as part of the measles eradication strategy in the Americas [17], and overall viral diagnostic capacity was enhanced. In 1996, rubella testing was added for all suspected measles cases with negative laboratory results for measles; additionally, guidelines for CRS surveillance were developed to detect infants!12 months of age with suspected CRS. By 1998, all 44 nations/territories were reporting rubella cases [18]. In 1999, measles and rubella surveillance systems were fully integrated [19], permitting simultaneous lab- Impact of Hemispheric Rubella Control CID 2006:43 (Suppl 3) S159
3 Figure 1. Rubella cases and number of rubella-containing vaccine doses administered in the World Health Organization Region of the Americas, Mexico, and the United States, Only first doses of rubella-containing vaccine given as part of the routine immunization schedule in Latin America are shown. oratory testing for all suspected measles and rubella cases. The number of nations/territories in the Americas reporting CRS cases increased from 18 in 1998 to all 44 in Rubella/CRS disease patterns. With increasing surveillance, the number of reported rubella cases in the Americas increased from 7640 in 1990 to a peak of 130,375 in After 1998, the number of nations/territories reporting rubella remained stable, but with increasing implementation of rubella vaccination strategies the number of reported rubella cases decreased to 3103 in 2004 (figure 1A). The number of reported CRS cases fell from a peak of 90 in 2000 to 27 in Mexico Rubella vaccination programs. Rubella vaccine was introduced into the childhood vaccination schedule in 1998, when measles monovalent vaccine was replaced with MMR in a 2- dose schedule directed at children 1 and 6 years of age. In 2000, to protect older age groups not reached by the routine childhood vaccination program, a strategy of MR vaccination of selected high-risk groups was initiated, including health care workers, teachers, military and police personnel, and tourist and migrant workers. In 2001, a vaccination campaign was conducted to deliver 1 dose of MR to junior and senior high S160 CID 2006:43 (Suppl 3) Dayan et al.
4 school students, and, in 2002, a permanent immunization program for adults was adopted. In 2004, a mass vaccination campaign of adolescents and adults years of age began. Indicators of rubella vaccination. The Mexican birth cohort is 2.2 million, and the total population is 106 million. During the period , 77.7 million doses of rubellacontaining vaccine were administered, which suggests that most of the population!40 years of age may have been vaccinated (figure 1B). During the same period, the reported vaccination coverage with the 1 dose of MMR among children 1 4 years of age was 195% [20]. Rubella/CRS surveillance. Since 1978, clinically diagnosed rubella cases have been reported to the Single Epidemiological Surveillance System (SUIVE). With the implementation of measles elimination in 1993, laboratory-confirmed cases have been reported through the Febrile Exanthematic Disease Surveillance System (FEDSS). Since 1997, the FEDDS has also been following women infected during pregnancy, to detect potential cases of CRS. Rubella/CRS disease patterns. From 1978 through 1999, rubella disease followed a recurrent pattern, with peaks occurring every 3 5 years. In 1997, 38,042 rubella cases were reported, and, in 1998 (the year in which the national rubella vaccination program was initiated), 51,846 cases were reported. Thereafter, the number of reported rubella cases fell steadily, reaching a low of 698 in 2004 (figure 1B). For the period , 110 infants with congenital malformations consistent with CRS were reported, 50 cases of which were laboratory confirmed [21]. In 2004, 5 CRS cases were reported, and 1 was laboratory confirmed [22]. United States Rubella vaccination programs. Rubella vaccine was introduced in the United States in 1969, targeting children 1 year of age to puberty [23]. In the 1970s, outbreaks were reported among adolescents and young adults, and additional recommendations targeting susceptible postpubertal females and persons in high-risk settings were established in The resurgence of measles in 1989 prompted the implementation of a 2-dose MMR schedule in 1989, and a goal of rubella elimination by 2000 was set the same year [24]. In the 1990s, rates of rubella disease declined, but a relative upward shift in the age distribution of rubella disease prompted renewed efforts to vaccinate adults missed by childhood vaccination programs, particularly women of childbearing age and persons born outside the United States. However, in contrast to the rest of the Americas, no mass campaigns were conducted among these groups or others, and the rubella elimination program continued to rely on ensuring high childhood coverage through routine vaccination. With evidence of continued rubella circulation in 2000, the goal of rubella elimination was reset to 2010, but the primary strategy of routine childhood vaccination remained unchanged [1, 6]. Indicators of rubella vaccination. The US birth cohort is 4 million, and the total population is 300 million [25]. During the period , when the epidemiological profile of rubella in the United States changed markedly, the annual number of doses administered remained stable, ranging from 10.8 to 14.2 million (figure 1C). National surveys suggested that childhood rubella vaccination coverage also remained stable at 190% during the same period [2]. Rubella/CRS surveillance. Rubella has been a reportable disease in the United States since By protocol, suspected cases are laboratory tested in public or commercial laboratories. As is reported in detail elsewhere, for the period , the surveillance system appeared to be both sensitive and specific for detection of rubella disease [26]. Rubella/CRS disease patterns. During , when the last major peak occurred, a total of 817 confirmed rubella cases were reported; during , the annual number of cases was never 125 and was a median of 13 (figure 1C). In 2001, for the first time, the rubella seasonal peak was lost and never regained, with cases occurring sporadically in time and place. In 1998, of 291 cases with known country of origin, 231 (79%) were among persons born outside the United States, of whom 210 (91%) were from Latin American countries, with 99 (43%) from Mexico alone. During , of the 45 cases with known country of origin, 10 (22%) were from Latin American countries, and 4 (9%) were from Mexico. A total of 24 infants with laboratory-confirmed CRS were born in the United States during Of the 23 mothers with known country of birth, 21 (91%) were born outside the United States, with 13 (62%) of these born in Mexico. Moreover, 10 (42%) of the 24 CRS cases were imported; 6 of the mothers (60%) were exposed in Mexico, and another 2 (20%) were exposed elsewhere in Latin America [1]. After 1999, the number of reported CRS cases declined steadily, reaching a low of 0 in DISCUSSION In summary, our data suggest that rubella control efforts in the Americas generally and in Mexico in particular may have had a significant positive influence on the success of rubella elimination efforts in the United States. After 2 decades of intensive vaccination efforts focusing on children, the United States had achieved, by the 1990s, high coverage and immunity levels, levels consistent with elimination of endemic transmission of rubella disease [2, 3]. Yet hundreds of cases continued to be reported each year, with large outbreaks occurring periodically [6]. In the 1990s, in contrast to previous decades, rubella occurred predominantly among adults and persons born in Latin America, especially Mexico. Then, in the late 1990s, Latin American nations and Mexico specifically began Impact of Hemispheric Rubella Control CID 2006:43 (Suppl 3) S161
5 Figure 2. Countries using rubella vaccine in their national immunization system, 1996 and Source: World Health Organization (WHO)/ Immunization, Vaccines, and Biologicals database, 2004 (192 WHO member states). Data as of September major rubella control efforts, with a marked increase in the number of rubella vaccine doses administered and a marked decrease in the number of rubella cases. Simultaneously, the epidemiological profile of rubella in the United States changed: the number of cases diminished to!25 annually, and the recurrent seasonal peak was lost. The shift to a pattern of isolated and sporadic disease suggested that endemic transmission had ended. This abrupt change in patterns of disease was not preceded by any change in vaccination strategy, by any increase in the number of rubella doses administered, or by any dramatic improvements in population-based immunity in the United States, but it was accompanied by a dramatic decrease in the number and proportion of cases in individuals born in Latin America. This suggests that the implementation of rubella control strategies in the Americas, particularly in Mexico, accelerated the decline of rubella disease to elimination levels in the United States. As an ecological and observational examination, our study has numerous limitations, and our findings should be interpreted with caution. Simultaneity and causation are not the same. One could argue that hemispheric rubella control may have been irrelevant decades of sustained high childhood vaccination coverage and the aging of a well-vaccinated population into adulthood may be sufficient to account for rubella elimination in the United States. Similarly, the relative suddenness in the shift of disease to an apparent elimination pattern in 2001 is difficult to explain on the basis of hemispheric disease trends. Furthermore, even in good surveillance systems, the number of reported cases generally underestimates true disease rates, particularly because half of all rubella cases are asymptomatic. Thus, the decrease in the number of US cases exceeds the reduction attributable to the decrease in documented importations from Latin America Elimination is conventionally defined as the end of ongoing transmission of a disease within a defined area, but infectious diseases do not necessarily respect national borders. Our study suggests that, although conditions to eliminate an infectious disease can be created within a single nation, actual elimination may be difficult to achieve without the help of a regional strategy and ongoing international cooperation. Global efforts at rubella control and elimination are still in their infancy. Although the proportion of the world s population living in countries with national rubella vaccination programs has doubled from 12% in 1996 to 25% in 2003 (figure 2), the world s most populous nations and the world s poorest nations have still not begun efforts at rubella control, much less elimination. The global burden of CRS remains high, with an estimated 100,000 infants born annually with blindness, S162 CID 2006:43 (Suppl 3) Dayan et al.
6 deafness, heart defects, or other disabilities attributable to rubella virus infection [27]. The impact of this disability burden may be highest in the least-developed nations. Rubella shares many clinical characteristics with measles, making joint surveillance efforts synergistic. In 2000, the WHO recommended that countries undertaking measles elimination should take the opportunity to eliminate rubella, through use of MR or MMR vaccine [28]. This approach has been undertaken by the Region of the Americas and countries with strong routine immunization programs in other regions, such as Europe and the Western Pacific [29]. Combining rubella and measles surveillance and vaccination activities will increase their cost-effectiveness [28]. We believe that the benefits of such a joint measlesrubella strategy have been demonstrated in the Americas [30]. The experience of rubella and CRS elimination in the United States demonstrates that endemic rubella transmission can be interrupted in a large geographic area with diverse populations. This experience also highlights the importance of regional control efforts and provides a well-documented example of the feasibility of rubella elimination in a country in the context of a region with established and successful elimination goals. Acknowledgments We acknowledge Charles LeBaron and Mary McCauley, for their assistance in editing this article. Financial support. Centers for Disease Control and Prevention. Supplement sponsorship. This article was published as part of a supplement entitled The Evidence for the Elimination of Rubella and Congenital Rubella Syndrome in the United States: A Public Health Achievement, sponsored by the Centers for Disease Control and Prevention. Potential conflicts of interest. All authors: no conflicts. References 1. Reef SE, Frey TK, Theall K, et al. The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention. JAMA 2002; 287: Bloom S, Smith P, Stanwyck C, Stokley S. Has the United States population been adequately vaccinated to achieve rubella elimination? Clin Infect Dis 2006; 43(Suppl 3):S141 5 (in this supplement). 3. Hyde TB, Kruszon-Moran D, McQuillan GM, Cossen C, Forghani B, Reef SE. Rubella immunity levels in the United States population: has the threshold of viral elimination been reached? Clin Infect Dis 2006; 43(Suppl 3):S (in this supplement). 4. Henderson RH, Keja J, Hayden G, Galazka A, Clements J, Chan C. Immunizing the children of the world: progress and prospects. Bull World Health Organ 1988; 66: World Health Organization. Rubella vaccines. WHO position paper. Available at: Accessed 1 December Reef SE, Redd SB, Abernathy E, Zimmerman L, Icenogle J. The epidemiological profile of rubella and congenital rubella syndrome in the United States, : the absence of endemic transmission. Clin Infect Dis 2006; 43(Suppl 3):S (in this supplement). 7. Pan American Health Organization, Division of Vaccines and Immunization. Final report: conclusions and recommendations. 12th meeting of the Technical Advisory Group on Vaccine Preventable Diseases, Guatemala. Washington, DC: Pan American Health Organization, Castillo-Solorzano C, Andrus JK. Rubella elimination and improving health care for women. Emerg Infect Dis 2004; 10: Irons B, Lewis MJ, Dahl-Regis M, Castillo-Solorzano C, Carrasco PA, De Quadros CA. Strategies to eradicate rubella in the English-speaking Caribbean. Am J Public Health 2000; 90: Pan American Health Organization. Rubella campaign in Chile. EPI Newsl 1999; 21: Morice A, Carvajal X, Leon M, et al. Accelerated rubella control and congenital rubella syndrome prevention strengthen measles eradication: the Costa Rican experience. J Infect Dis 2003; 187(Suppl 1):S Pan American Health Organization. Brazil accelerates control of rubella and prevention of congenital rubella syndrome program. EPI Newsl 2002; 24: Pan American Health Organization. Sustaining immunization program elimination of rubella and congenital rubella syndrome (CRS). 44th Meeting of the Pan American Directing Council (Washington, DC), document CD44/11. Washington, DC: Pan American Health Organization, Available at: cd44-11-e.pdf. Accessed 3 August Andrus JK, Periago MR. Elimination of rubella and congenital rubella syndrome in the Americas: another opportunity to address inequities in health. Rev Panam Salud Publica 2004; 15: Pan American Health Organization. Health situation in the Americas: basic indicators. PAHO Basic Indicator Database. Available at: Accessed 5 August Pan American Health Organization. Measles eradication field guide. Technical paper 41. Washington DC: Pan American Health Organization, de Quadros CA, Olive JM, Hersh BS, et al. Measles elimination in the Americas: evolving strategies. JAMA 1996; 275: Castillo-Solorzano C, Carrasco P, Tambini G, Reef S, Brana M, De Quadros CA. New horizons in the control of rubella and prevention of congenital rubella syndrome in the Americas. J Infect Dis 2003; 187(Suppl 1):S Pan American Health Organization. Measles and rubella surveillance integration in the Americas. EPI Newsl 2000; 22: World Health Organization. WHO vaccine preventable diseases monitoring system 2003 global summary. Geneva: World Health Organization, Measles, rubella, and congenital rubella syndrome United States and Mexico, MMWR Morb Mortal Wkly Rep 2000; 49: , Dirección General de Epidemiología. Boletín epidemiológico. Available at: Accessed 1 December Centers for Disease Control and Prevention. Elimination of rubella and congenital rubella syndrome United States, MMWR Morb Mortal Wkly Rep 2005; 54: Hinman AR, Orenstein WR, Papania MJ. Evolution of measles elimination strategies in the United States. J Infect Dis 2004; 189:S US Census Bureau. United States census Available at: Accessed 21 September Averhoff F, Zucker J, Vellozzi C, et al. Adequacy of surveillance to detect endemic rubella transmission in the United States. Clin Infect Dis 2006; 43(Suppl 3):S151 7 (in this supplement). 27. Robertson SE, Featherstone DA, Gacic-Dobo M, Hersh BS. Rubella and congenital rubella syndrome: global update. Rev Panam Salud Publica 2003; 14: World Health Organization, Department of Vaccines and Biologicals. Report of a meeting on preventing congenital rubella syndrome: immunization strategies, surveillance needs. WHO/V&B/ Geneva: World Health Organization, Strebel PM, Henao-Restrepo AM, Hoekstra E, Olive JM, Papania MJ, Cochi SL. Global measles elimination efforts: the significance of measles elimination in the United States. J Infect Dis 2004; 189(Suppl 1): S Tambini G, Andrus JK, Fitzsimmons JW, Roses Periago M. Regional immunization programs as a model for strengthening cooperation among nations. Pan Am J Public Health 2006; 20(1):54 9. Impact of Hemispheric Rubella Control CID 2006:43 (Suppl 3) S163
Progress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere,
1 Introduction: Progress Toward Rubella and Congenital Rubella Syndrome Elimination in the Western Hemisphere, 2003-2008 1 Enhanced measles elimination activities in the Region of the Americas during the
More informationRubella and CRS Elimination in the Americas
Rubella and CRS Elimination in the Americas Jon Kim Andrus, MD Deputy Director, PAHO Rome, Italy 8-10 February 2012 Presentation Opportunities for a rubella elimimation initiative The impact of the initiative
More informationAccelerated Rubella Control and Congenital Rubella Syndrome Prevention Strengthen Measles Eradication: The Costa Rican Experience
SUPPLEMENT ARTICLE Accelerated Rubella Control and Congenital Rubella Syndrome Prevention Strengthen Measles Eradication: The Costa Rican Experience Ana Morice, 1 Xinia Carvajal, 1 Mario León, 2 Vicenta
More informationMeasles and Rubella Elimination Initiatives in the Americas: Lessons Learned and Best Practices
SUPPLEMENT ARTICLE Measles and Rubella Elimination Initiatives in the Americas: Lessons Learned and Best Practices Carlos Castillo-Solorzano, Christina Marsigli, M.Carolina Danovaro-Holliday, Cuauhtémoc
More informationSustaining Immunization in Developing Countries: The Future We Make
Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication
More informationGlobal Measles Elimination Efforts: The Significance of Measles Elimination in the United States
SUPPLEMENT ARTICLE Global Measles Elimination Efforts: The Significance of Measles Elimination in the United States Peter M. Strebel, 1 Ana-Maria Henao-Restrepo, 3 Edward Hoekstra, 4 Jean-Marc Olivé, 3
More informationGOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights
GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION (indicator G2.2) Highlights As of December 2014, 140 Member States had introduced rubella vaccines; coverage, however, varies from 12% to 94% depending on region.
More informationLessons Learned and Best Practices of Achieving and Maintaining Measles and Rubella Elimination in the Americas
Lessons Learned and Best Practices of Achieving and Maintaining Measles and Rubella Elimination in the Americas Jon Kim Andrus, MD Deputy Director, PAHO Rome, Italy 8-10 February, 2012 Presentation Outline
More informationFramework for Verifying Elimination of Measles and Rubella SAGE Working Group on Measles and Rubella (Draft of 18 October 2012)
Framework for Verifying Elimination of Measles and Rubella SAGE Working Group on Measles and Rubella (Draft of 18 October 2012) Preamble The Global Vaccine Action Plan 2012-2020, established the target
More informationWHO position paper on rubella vaccines
WHO position paper on rubella vaccines Progress Toward Rubella Elimination And CRS Prevention in Europe February 2012 10-8 Rome, Italy Peter Strebel, WHO and Susan Reef, CDC Rubella Vaccines WHO Position
More information52nd DIRECTING COUNCIL 65th SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 52nd DIRECTING COUNCIL 65th SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, from 30 September to 4 October 2013 Provisional Agenda Item
More informationMeasles Surveillance in the United States: An Overview
SUPPLEMENT ARTICLE Measles Surveillance in the United States: An Overview Dalya Güriş, Rafael Harpaz, Susan B. Redd, Natalie J. Smith, a and Mark J. Papania National Immunization Program, Centers for Disease
More informationIntroduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI
Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making LUCIA HELENA DE OLIVEIRA AND BARBARA JAUREGUI 2 Introduction of New Vaccines in Latin America and the Caribbean: Decision-Making
More informationAn aggressive approach for measles outbreak among adolescents in Barranquilla, Colombia, 2011
Closing immunity gaps in older children and adults towards measles and rubella elimination: Lessons learned and challenges. Siena, Italy, May 10-11 2016 An aggressive approach for measles outbreak among
More informationUpdate/Le point. Principles of measles control* R.H. Henderson,2 C.J. Clements,3 R.T. Chen,4 & P.A. Patriarca5
Update/Le point Principles of measles control* F.T. Cutts,, R.H. Henderson, C.J. Clements,3 R.T. Chen,4 & P.A. Patriarca5 WHO's Expanded Programme on Immunization has significantly helped to reduce global
More informationRegional Update Influenza (August 16, h GMT; 12 h EST)
Regional Update Influenza (August 16, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More information50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September -1 October 2010 CD50/DIV/9 ORIGINAL: SPANISH
More information*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a
*This response is constantly evolving and recommendations in this presentation may change over time, please call your district epidemiologist or a GDPH epidemiologist 404-657-2588, 8-5 pm M-F for current
More informationUnderstanding the Roles of Different Bodies in Vaccine Decision Making: The Caribbean EPI Experience
Understanding the Roles of Different Bodies in Vaccine Decision Making: The Caribbean EPI Experience Prof J Peter Figueroa Department of Community Health & Psychiatry University of the West Indies Kingston,
More informationCurrent Incident Status of Vaccine-Preventable Bacterial and Viral Infectious Diseases in Japan
Research and Reviews Current Incident Status of Vaccine-Preventable Bacterial and Viral Infectious Diseases in Japan JMAJ 53(2): 106 110, 2010 Hajime KAMIYA,* 1 Tomoe SHIMADA,* 2 Nobuhiko OKABE* 3 Abstract
More informationTaking vaccine effectiveness into public health decision making: The ProVac Example
http://www.paho.org/provac Taking vaccine effectiveness into public health decision making: The ProVac Example Evaluating dengue effectiveness workshop June 12 th, 2014 Washington, DC Cara Bess Janusz
More information28th PAN AMERICAN SANITARY CONFERENCE 64th SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 28th PAN AMERICAN SANITARY CONFERENCE 64th SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 17-21 September 2012 Provisional Agenda Item
More information20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus since April 2009.
B. UPDATE ON THE PANDEMIC (H1N1) 2009 CD50/INF/6 (Eng.) - 7 - Annex B Background 20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus
More informationGenetic Disorders and Congenital Defects in Latin America and the Caribbean
Genetic Disorders and Congenital Defects in Latin America and the Caribbean Victor B. Penchaszadeh, MD, MSPH Columbia University, New York and Pan American Health Organization CAPABILITY Workshop Lund,
More informationChapter 1 Overview of Tuberculosis Epidemiology in the United States
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States... 3 TB Disease Trends in the United
More informationProceedings of the SAGE Working Group on Rubella
Proceedings of the SAGE Working Group on Rubella March 17, 2011 1 Preamble Rubella is usually a mild viral rash illness in children and adults; however, infection early in a woman s pregnancy, particularly
More informationBuilding Zika preparedness in the Region of the Americas: research response
Update 23 September 2016 Building Zika preparedness in the Region of the Americas: research response Global Research Collaboration for Infectious Disease Preparedness meeting, Sao Paulo, November 30 Ludovic
More informationdeveloping countries in Latin America?
. How have rotavirus vaccines worked in developing countries in Latin America? Brendan Flannery, Pan American Health Organization, Brazil and Lúcia De Oliveira, Immunization Unit/FCH, Washington, DC 9th
More informationEvolution of Measles Elimination Strategies in the United States
SUPPLEMENT ARTICLE Evolution of Measles Elimination Strategies in the United States Alan R. Hinman, 1 Walter A. Orenstein, 2 and Mark J. Papania 2 1 Task Force for Child Survival and Development, Decatur,
More informationRegional Update Pandemic (H1N1) 2009 (July 6, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 29 (July 6, 21-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More informationFINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA
Comprehensive Family Immunization Family and Community Health Area FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES 24-26 AUGUST 2009, COSTA RICA Epidemiological
More informationHEALTH. Sexual and Reproductive Health (SRH)
HEALTH The changes in global population health over the last two decades are striking in two ways in the dramatic aggregate shifts in the composition of the global health burden towards non-communicable
More informationSIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat
SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item 12.17 16 April 2009 Viral hepatitis Report by the Secretariat THE DISEASES AND BURDEN 1. The group of viruses that cause acute and/or chronic
More informationCopyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN
UNAIDS DATA TABLES 2011 Copyright 2011 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved ISBN 978-92-9173-945-5 UNAIDS / JC2225E The designations employed and the presentation of
More informationMeasles and Rubella Global Update SAGE 19 October 2017
Measles and Rubella Global Update SAGE 19 October 2017 Alya Dabbagh WHO HQ, IVB/EPI Global update Overview Regional progress and challenges M&RI Midterm Review updates Economics of measles and rubella
More informationDR. CLAUDINA E. CAYETANO REGIONAL MENTAL ADVISOR Pan-American Health Organization/ World Health Organization
DR. CLAUDINA E. CAYETANO REGIONAL MENTAL ADVISOR Pan-American / World Outline Facts and Figures Suicide a major Public problem Suicide in the Americas Risk and Protective factors and related interventions
More informationRegional Update Pandemic (H1N1) 2009
Regional Update Pandemic (H1N1) 2009 (September 04, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 34 (EW 34), from 23 August to 29 August, 20 countries reported
More informationMeasles and rubella monitoring January 2015
Measles and rubella monitoring January 215 Reporting on January December 214 surveillance data and epidemic intelligence data to the end of January 215 Main developments Measles During the 12-month period
More informationThe Eradication of Poliomyelitis in Egypt: Critical Factors Affecting Progress to Date
S56 The Eradication of Poliomyelitis in Egypt: Critical Factors Affecting Progress to Date R. Bruce Aylward, Esmat Mansour, EI Said Aly Don, Ahmed Haridi, Abdulla Abu EI Kheir, and AtefHassan World Health
More informationOverview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015
Overview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015 Ana F. Carvalho, MBA, MPH Director, Special Projects Vaccine Advocacy and Education Presented by: Jacqueline Lim
More informationRegional Update Pandemic (H1N1) 2009 (March 15, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (March 15, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More informationGlobal reductions in measles mortality and the risk of measles resurgence
Global reductions in measles mortality 2000 2008 and the risk of measles resurgence Measles is one of the most contagious human diseases. In 1980 before the use of measles vaccine was widespread, there
More informationProgress Toward Measles Elimination in the Russian Federation,
SUPPLEMENT ARTICLE Progress Toward Measles Elimination in the Russian Federation, 2003 2009 G. Onishchenko, 1 E. Ezhlova, 1 A. Gerasimova, 2 O. Tsvirkun, 2 S. Shulga, 2 G. Lipskaya, 3 T. Mamayeva, 2 V.
More informationMeasles, Mumps and Rubella. Ch 10, 11 & 12
Measles, Mumps and Rubella Ch 10, 11 & 12 Measles Highly contagious viral illness First described in 7th century Near universal infection of childhood in prevaccination era Remains the leading cause of
More informationSeropositivity Rates for Measles, Mumps, and Rubella IgG and Associated Cost. with Testing and Revaccination
CVI Accepts, published online ahead of print on 23 January 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00503-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9
More information50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September-1 October 2010 Provisional Agenda Item 4.10
More informationTime to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention
Time to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and
More informationRegional Update Pandemic (H1N1) 2009 (July 19, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 9 (July 19, - 17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National Influenza
More informationMeasles: United States, January 1 through June 10, 2011
Measles: United States, January 1 through June 10, 2011 Preeta K. Kutty, MD, MPH Measles, Mumps, Rubella and Polio Team Division of Viral Diseases Centers for Disease Control and Prevention Atlanta, GA
More informationHPV Vaccines: Background and Current Status
HPV Vaccines: Background and Current Status Bogota, Colombia, 2007 Jon Kim Andrus, MD HPV and Cervical Cancer Evidence that HPV is essential: Documented molecular studies of cervical cancer Case-control
More informationInfluenza Vaccine Use In the Americas
Influenza Vaccine Use In the Americas Network for Evaluation of Influenza Vaccine Effectiveness REVELAC-i Alba Maria Ropero-Alvarez Comprehensive Family Immunization Unit PAHO/FGL/IM Global Vaccine and
More informationIntroduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa
Introduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa Nigeria Center for Disease Control Federal Ministry of Health Abuja July 2015 Outline 1. Measles disease 2. Progress towards
More information3. CONCLUSIONS AND RECOMMENDATIONS
3. CONCLUSIONS AND RECOMMENDATIONS 3.1 Polio Endgame Strategy Conclusions 1. The TAG welcomes the RCC conclusion that Western Pacific Region maintains its polio-free status, and commends China for the
More informationEradication of Wild Poliovirus from the Americas: Acute Flaccid Paralysis Surveillance,
S37 Eradication of Wild Poliovirus from the Americas: Acute Flaccid Paralysis Surveillance, 1988-1995 Ciro A. de Quadros, Bradley S. Hersh, Jean-Marc Olive, Jon K. Andrus, Claudio M. da Silveira, and Peter
More informationMeasles Mortality Reduction Contributes Substantially to Reduction of All Cause Mortality Among Children Less Than Five Years of Age,
SUPPLEMENT ARTICLE Measles Mortality Reduction Contributes Substantially to Reduction of All Cause Mortality Among Children Less Than Five Years of Age, 1990 2008 Maya M. V. X. van den Ent, 1 David W.
More informationFrequently asked questions (FAQs) on MR vaccination campaign
Frequently asked questions (FAQs) on MR vaccination campaign What are measles/rubella diseases? Measles is a highly infectious disease causing illness and death due to complications in the form of diarrhea,
More informationHepatitis B and C in the Spotlight: A public health response in the Americas. Key Messages
2017 highlights Hepatitis B and C in the Spotlight: A public health response in the Americas Key Messages Regarding the national structures developed to support the response to the viral hepatitis epidemics,
More informationControlling Vaccine Preventable Diseases in the US and Global Immunization Efforts
Controlling Vaccine Preventable Diseases in the US and Global Immunization Efforts Anne Schuchat, MD RADM, US Public Health Service Assistant Surgeon General Director, National Center for Immunization
More informationMeasles Containing Vaccines. UNICEF Supply Division Industry Consultation Meeting January 2012
Measles Containing Vaccines UNICEF Supply Division Industry Consultation Meeting 25-26 January 2012 Content Measles monovalent vaccine: Programme Updates and Procurement Overview Measles and Rubella vaccine:
More informationPart I. Health-related Millennium Development Goals
11 1111111111111111111111111 111111111111111111111111111111 1111111111111111111111111 1111111111111111111111111111111 111111111111111111111111111111 1111111111111111111111111111111 213 Part I Health-related
More informationFrequently asked questions (FAQs) on MR vaccination campaign. Training Workshop for Measles-Rubella Vaccination Campaigns
Frequently asked questions (FAQs) on MR vaccination campaign Training Workshop for Measles-Rubella Vaccination Campaigns What are measles/rubella diseases? Measles is a highly infectious disease causing
More informationBack to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office
Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office SAGE, Geneva 27 October 2009 Rebecca Martin Targeted Diseases and
More informationMeasles Strategic Planning Tool: Analysis of MCV strategies in developing countries. Emily Simons 29 January 2009
Measles Strategic Planning Tool: Analysis of MCV strategies in developing countries Emily Simons 29 January 2009 Overview The MSP tool Results by question For Indian states: what is best strategy to accelerate
More informationB. PLAN OF ACTION FOR IMPLEMENTING THE GENDER EQUALITY POLICY
Page 7 B. PLAN OF ACTION FOR IMPLEMENTING THE GENDER EQUALITY POLICY Background 1. Member States approved the Pan American Health Organization s (PAHO) Gender Equality Policy during the 46th Directing
More informationRegional Update EW 09 Influenza (March 15, h GMT; 12 h EST)
Regional Update EW 09 Influenza (March 15, 2011-17 h GMT; 12 h EST) The information presented in this update is based on data provided by Ministries of Health and National Influenza Centers of Member States
More informationChallenges for viral hepatitis prevention in Latin American
Challenges for viral hepatitis prevention in Latin American One in three people on earth has been exposed to hepatitis B or C viruses (HBV and HCV); HBV and HCV are responsible for 57% of cirrhosis and
More informationRESEARCH ON AIDS IN LATIN AMERICA AND THE CARIBBEAN
ACHR 29/93.10 Original: Spanish RESEARCH ON AIDS IN LATIN AMERICA AND THE CARIBBEAN Division of Communicable Diseases Prevention and Control Program of AIDS and Sexually Transmitted Diseases July 1993.1..
More informationNSW Annual Vaccine-Preventable Disease Report, 2011
NSW Annual Vaccine-Preventable Disease Report, 211 Alexander Rosewell A,B, Paula J. Spokes A and Robin E. Gilmour A A Health Protection NSW B Corresponding author. Email: arosw@doh.health.nsw.gov.au Abstract:
More informationFigure 1: Suspected and confirmed Zika virus cases reported by countries and territories in the Americas, by epidemiological week (EW)
Zika - Epidemiological Update 17 March 2016 Zika virus Incidence and trends Available data reported suggests a downward trend in reporting of Zika virus cases in the Region of the Americas (Figure 1).
More informationWHO Technical Consultation on the severity of disease caused by the new influenza A (H1N1) virus infections
WHO Technical Consultation on the severity of disease caused by the new influenza A (H1N1) virus infections Original short summary posted 6 May 2009. Revised full report posted May 9 2009. On 5 May 2009
More informationMarta-Louise Ackers, a Robert E Quick, a Christopher J Drasbek, b Lori Hutwagner c and Robert V Tauxe a
O International Epldemiological Association 998 Printed in Great Britain International Journal of Epidemiology 998:27:-4 Are there national risk factors for epidemic cholera? The correlation between socioeconomic
More informationWHO position paper on rubella vaccines
WHO position paper on rubella vaccines Geneva, Switzerland Published in WER July 2011 Rubella and congenital rubella syndrom Rubella is an acute, viral disease tradi)onally affec)ng children and young
More informationRegional Update EW 44 Influenza (November 15, h GMT; 12 h EST)
Regional Update EW 44 Influenza (November 15, 2011-17 h GMT; 12 h EST) PAHO interactive influenza data: http://ais.paho.org/phip/viz/ed_flu.asp Influenza Regional Reports: www.paho.org/influenzareports
More informationAdverse Event GACVS. Global Advisory Committee on Vaccine Safety, 910 June 2005
Adverse Event The Committee considered the decision taken by the Government of Japan on 30 May 2005 to suspend routine vaccination with the mouse brainderived Japanese encephalitis (JE) vaccine currently
More informationFINAL REPORT TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES AUGUST 2009, COSTA RICA
TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES 24-26 AUGUST 2009, COSTA RICA FINAL REPORT XVIII TAG MEETING, COSTA RICA, 2009 DRAFT FINAL REPORT (2 SEPTEMBER) 1 TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE
More informationRegional Update Pandemic (H1N1) 2009 (January 19, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (January 19, - 17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More informationDRAFT of 25 Mar 2004 WORLD HEALTH ORGANIZATION
DRAFT of 25 Mar 2004 WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC WESTERN PACIFIC REGIONAL GUIDELINES: INTRODUCING RUBELLA VACCINE Contents Summary...3 Purpose...3 Background...3 Disease
More informationSave the Children s Zika Virus Response: Addressing Education and Personal Protection Needs in the Americas Request for Support
Save the Children s Zika response strategy in 11 countries in the Americas focuses on increasing awareness of the virus and its prevention, in part by reaching women such as this Guatemalan mother through
More informationRegional Immunization Action Plan for the Americas Progress report 2015
Regional Immunization Action Plan for the Americas Progress report 2015 Introduction During the 54th Directing Council meeting of the Pan American Health Organization (PAHO) in September 2015, Member States
More informationRegional Update Pandemic (H1N1) 2009
Regional Update Pandemic (H1N1) 2009 (September 18, 2009-22 h GMT; 17 h EST) Update on the Qualitative Indicators For Epidemiological Week 36 (EW 36), from 6 September to 12 September, 17 countries reported
More informationJanuary 2006 HepTalk Listserv
January 2006 HepTalk Listserv Announcements from HepTalk Our focus for January 2006 is on the updated Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention
More informationNavigating vaccine introduction: a guide for decision-makers JAPANESE ENCEPHALITIS (JE) Module 1. Does my country need JE vaccine?
Navigating vaccine introduction: a guide for decision-makers JAPANESE ENCEPHALITIS (JE) Module 1 Does my country need JE vaccine? 1 about this guide Japanese encephalitis (JE), a viral infection of the
More informationMeasles Elimination in NZ. Dr Tom Kiedrzynski Principal Adviser, Communicable diseases, Ministry of Health
Measles Elimination in NZ Dr Tom Kiedrzynski Principal Adviser, Communicable diseases, Ministry of Health Presentation Outline International background WHO requirements Overview of the measles situation
More informationFISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated ) USAID Global Health Programs (GHP) and State Department
FISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated 2.13.19) Contact: Brian Massa, Senior Manager for Global Health Advocacy, Shot@Life (bmassa@unfoundation.org) USAID Global Health Programs (GHP) and State
More informationMonitoring the achievement of the health-related Millennium Development Goals
SIXTY-SIXTH WORLD HEALTH ASSEMBLY A66/13 Provisional agenda item 14.1 14 May 2013 Monitoring the achievement of the health-related Millennium Development Goals Report by the Secretariat 1. In response
More informationPandemic (H1N1) (August 28, h GMT; 12 h EST) Update on the qualitative indicators
Regional Update Pandemic (H1N1) 29 (August 28, 29-17 h GMT; 12 h EST) Update on the qualitative indicators For Epidemiological Week 33 (EW 33), from 16 August to 22 August, 22 countries reported updated
More informationExpanded Programme on Immunization (EPI)
Bhutan 2017 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles containing
More informationFERTILITY DECLINE AND PUBLIC POLICIES TO ADDRESS POPULATION RIGHTS: PERSPECTIVE FROM LATIN AMERICA
FERTILITY DECLINE AND PUBLIC POLICIES TO ADDRESS POPULATION RIGHTS: PERSPECTIVE FROM LATIN AMERICA Suzana Cavenaghi ENCE/IBGE, Brazil United Nations Expert Group Meeting on Fertility, Changing Population
More informationThe number of newly identified HIV cases decreased. There was a sharp drop in both male and female HIV rates in 2013.
Purpose This report examines HIV and AIDS surveillance data reported in Saskatchewan to provide an up-to-date profile of individuals diagnosed with HIV and AIDS in the province. The annual report focuses
More information_flu.asp. States. North. The Caribbean and (Cuba, South. South. B was observed.
North America: Influenza activity remained low in the sub-region with co-circulation of influenza A(H1N1)pdm09, A(H3N2) and influenza B. In the United States, no new humann infections with influenza A(H3N2)
More informationReducing differences in the uptake of immunisation (PH21): Frequently asked questions for staff in Sure Start Children s Centres
Reducing differences in the uptake of immunisation (PH21): Frequently asked questions for staff in Sure Start Children s Centres This Frequently Asked Questions tool accompanies the public health guidance:
More informationDecline in Mortality Due to Varicella after Implementation of Varicella Vaccination in the United States
The new england journal of medicine original article Decline in Mortality Due to Varicella after Implementation of Varicella Vaccination in the United States Huong Q. Nguyen, M.P.H., Aisha O. Jumaan, Ph.D.,
More informationRegional Update Pandemic (H1N1) 2009 (May 24, h GMT; 12 h EST)
Regional Update Pandemic (H1N1) 2009 (May 24, 2010-17 h GMT; 12 h EST) The information contained within this update is obtained from data provided by Ministries of Health of Member States and National
More informationEverything you ever wanted to know about Zika Virus Disease
Everything you ever wanted to know about Zika Virus Disease (in 14 slides) Jon Temte, MD/PhD University of Wisconsin School of Medicine and Public Health 28 January 2016 Zika Virus mosquito-borne flavivirus
More informationGlobal Vaccine Action Plan
Global Vaccine Action Plan Regional reports on progress towards GVAP RVAP goals Annex to the GVAP Secretariat Annual Report 2016 World Health Organization 2016 All rights reserved. Publications of the
More informationin control group 7, , , ,
Q1 Rotavirus is a major cause of severe gastroenteritis among young children. Each year, rotavirus causes >500,000 deaths worldwide among infants and very young children, with 90% of these deaths occurring
More informationImpact and effectiveness of national immunisation programmes. David Green, Nurse Consultant, Immunisations Public Health England
Impact and effectiveness of national immunisation programmes David Green, Nurse Consultant, Immunisations Public Health England Session objectives Immunisation planning and implementation The impact and
More informationPandemic (H1N1) (August 14, h GMT; 12 h EST) Update on the Qualitative Indicators
Regional Update Pandemic (H1N1) 2009 (August 14, 2009-17 h GMT; 12 h EST) Update on the Qualitative Indicators For epidemiological week 31 (EW 31, August 2 to August 8) 17 countries have reported updated
More informationGeneral Description. Significance
General Description The Zika virus is a member of the Flavivirus family, and is a small, enveloped virus (easy to kill with a hospital disinfectant). Zika virus is an emerging mosquito-borne virus that
More information